<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011367</article-id><article-id pub-id-type="publisher-id">ACM-38479</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_74039876.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  房颤合并肥厚型梗阻性心肌病心腔内超声指导下行肺静脉隔离附加室间隔消融一例
  Catheter Ablation with CARTO Sound Technology of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Case Report
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>玉娇</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>丰强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>姗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>路</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>安</surname><given-names>毅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院心内科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院肾病科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2433</fpage><lpage>2438</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肥厚型梗阻性心肌病(HOCM)患者合并心房颤动的发生率为一般人群的4~6倍，特别是HOCM合并永久性房颤的患者预后较差，而维持窦性心律可能会对预后有一定程度的改善。目前，对于症状性房颤患者的治疗主要推荐射频消融术。研究表明，房颤消融术后可明显改善患者心衰住院率以及生活质量。HOCM并房颤患者可出现进行性心衰加重、卒中等风险。目前，室间隔射频消融术在心腔内超声指导下能准确定位室间隔，结合心内电解剖标测，从而实现安全、有效的消融，为HOCM患者提供了更为安全、有效的替代治疗方案。本例患者HOCM合并房颤，选择心腔内超声指导下室间隔 + 房颤射频消融术治疗优势突出，即可安全、有效地解决左室流出道梗阻，又可治疗房颤维持窦性心律。
    The incidence of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy (HOCM) is 4 - 6 times higher than that in the general population. Especially in patients with permanent atrial fibrillation and HOCM, the prognosis is poor. Maintaining sinus rhythm may improve the prognosis to some extent. At present, radiofrequency ablation is recommended for symptomatic atrial fibrillation. Studies have shown that AF ablation can significantly improve the hospitalization rate and quality of life of patients with heart failure. Patients with HOCM and atrial fibrillation may have the risk of progressive heart failure and stroke. At present, the ventricular septum radiofrequency ablation can accurately locate the ventricular septum under the guidance of intracardiac echocardiography, combined with intracardiac electroanatomic mapping, so as to achieve safe and effective ablation, and provide a much safer and effective alternative treatment for patients with HOCM. This case of HOCM complicated with atrial fibrillation was treated by intracardiac ultrasound-guided ventricular septum + atrial fibrillation radiofrequency ablation, which can solve the obstruction of left ventricular outflow tract safely and effectively, treat atrial fibrillation and maintain sinus rhythm. 
  
 
</p></abstract><kwd-group><kwd>肥厚型梗阻性心肌病，房颤，心腔内超声，室间隔 + 房颤射频消融术, Hypertrophic Obstructive Cardiomyopathy</kwd><kwd> Atrial Fibrillation</kwd><kwd> Intracardiacechocardiography</kwd><kwd> Ventricular Septum + Atrial Fibrillation Radiofrequency Ablation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肥厚型梗阻性心肌病(HOCM)患者合并心房颤动的发生率为一般人群的4~6倍，特别是HOCM合并永久性房颤的患者预后较差，而维持窦性心律可能会对预后有一定程度的改善。目前，对于症状性房颤患者的治疗主要推荐射频消融术。研究表明，房颤消融术后可明显改善患者心衰住院率以及生活质量。HOCM并房颤患者可出现进行性心衰加重、卒中等风险。目前，室间隔射频消融术在心腔内超声指导下能准确定位室间隔，结合心内电解剖标测，从而实现安全、有效的消融，为HOCM患者提供了更为安全、有效的替代治疗方案。本例患者HOCM合并房颤，选择心腔内超声指导下室间隔 + 房颤射频消融术治疗优势突出，即可安全、有效地解决左室流出道梗阻，又可治疗房颤维持窦性心律。</p></sec><sec id="s2"><title>关键词</title><p>肥厚型梗阻性心肌病，房颤，心腔内超声，室间隔 + 房颤射频消融术</p></sec><sec id="s3"><title>Catheter Ablation with CARTO Sound Technology of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Case Report<sup> </sup></title><p>Chao Chen<sup>1</sup>, Yujiao Wei<sup>2</sup>, Hao Zhang<sup>1</sup>, Fengqiang Xu<sup>1</sup>, Shan Li<sup>1</sup>, Jun Lu<sup>1</sup>, Yi An<sup>1*</sup></p><p><sup>1</sup>Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/1-1571626x5_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Oct. 28<sup>th</sup>, 2020; published: Nov. 4<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/1-1571626x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The incidence of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy (HOCM) is 4 - 6 times higher than that in the general population. Especially in patients with permanent atrial fibrillation and HOCM, the prognosis is poor. Maintaining sinus rhythm may improve the prognosis to some extent. At present, radiofrequency ablation is recommended for symptomatic atrial fibrillation. Studies have shown that AF ablation can significantly improve the hospitalization rate and quality of life of patients with heart failure. Patients with HOCM and atrial fibrillation may have the risk of progressive heart failure and stroke. At present, the ventricular septum radiofrequency ablation can accurately locate the ventricular septum under the guidance of intracardiac echocardiography, combined with intracardiac electroanatomic mapping, so as to achieve safe and effective ablation, and provide a much safer and effective alternative treatment for patients with HOCM. This case of HOCM complicated with atrial fibrillation was treated by intracardiac ultrasound-guided ventricular septum + atrial fibrillation radiofrequency ablation, which can solve the obstruction of left ventricular outflow tract safely and effectively, treat atrial fibrillation and maintain sinus rhythm.</p><p>Keywords:Hypertrophic Obstructive Cardiomyopathy, Atrial Fibrillation, Intracardiacechocardiography, Ventricular Septum + Atrial Fibrillation Radiofrequency Ablation</p><disp-formula id="hanspub.38479-formula1"><graphic xlink:href="//html.hanspub.org/file/1-1571626x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1571626x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-1571626x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>心房颤动是肥厚性心肌病较为常见的一种合并疾病，肥厚性心肌病的发病率约为1/500，据估计在我国约有260万人患有此病。而肥厚型梗阻性心肌病(HOCM)患者合并心房颤动的发生率为一般人群的4~6倍。既往研究表明，房颤合并肥厚性心肌病患者预后较差，且合并房颤患者的死亡风险、心力衰竭发病率以及缺血型卒中的风险明显提高。目前，对于房颤合并肥厚性心肌病的治疗包括药物、酒精/射频以及外科手术等治疗。本个案对患者性心腔内超声指导下室间隔 + 房颤射频消融术，为HOCM合并房颤患者提供一种更安全有效的治疗方案。</p><p>病人，男，59岁，因“发作性心慌7年，加重3月”入院。患者7年前无明显诱因下出现心慌，伴胸闷、气短、出汗，呈发作性，以活动后或劳累下为著，自述每次持续7~8小时后缓解。无头晕、头痛，无心前区疼痛，无咳嗽、咳痰、咯血等不适。未予系统治疗。3年前再次出现心慌于我院门诊就诊，行心电图检查示：① 异位心律 心房颤动快速型；② 多导联ST段改变。(见图1，A)心脏超声示：左室舒张末期内径45 mm，射血分数66%，左房扩大，左心室壁非均匀性增厚，室间隔最厚处16 mm，左室后壁厚13 mm，室间隔与左室后壁之比约1.23，收缩期左室流出道前向血流流速增快，峰值流速2.8 m/s，峰值压差约67 mmHg。① 肥厚性心肌病(梗阻型) 左室流出道血流梗阻(轻度) 左房扩大 左室舒张功能减低；② 心瓣膜退行性变 二尖瓣反流(轻度)主动脉瓣反流(轻度)三尖瓣反流(轻度)。(见图2，E)。诊断为：心房颤动、肥厚型心肌病(梗阻型)。给予倍他乐克qd控制心室率治疗。3月前患者感心慌症状较前加重，发作较前频繁，持续时间较前延长，为行进一步诊治，门诊以“阵发性心房颤动”收住我科。入院查体：T：36.5℃，P：73次/分，R：18次/分，BP：120/66 mmHg。神志清，精神可，双肺呼吸音清，未闻及干湿性啰音。心率73次/分，律齐，于胸骨左缘3、4肋间可闻及粗糙的3/6级收缩期喷射样杂音。腹软，无压痛及反跳痛，双下肢无水肿。辅助检查：血常规、血凝、肝肾功等未见明显异常。胸部CT：① 左肺散在小结节；② 左肺斜裂增厚。心脏超声：左室舒张末期内径44 mm，射血分数63%，左房扩大，左心室壁非均匀性增厚，室间隔最厚处15 mm，左室后壁厚13 mm，室间隔与左室后壁之比约1.15，收缩期左室流出道前向血流流速增快，峰值流速2.7 m/s，峰值压差约62 mmHg。① 考虑肥厚型心肌病 左房扩大(轻度)左室心肌肥厚(非对称性) ② 主动脉瓣反流(轻度)二尖瓣反流(轻度)三尖瓣反流(轻度) ③ 左室舒张功能减低。(见图2，F)心电图：① 窦性心律② 多导联ST-T改变(见图1，B)。肺静脉CTA：未见明显血栓形成。患者既往身体健康。结合患者主诉、现病史、既往史、辅助检查等，最终诊断为：阵发性心房颤动 肥厚性梗阻型心肌病。排除手术禁忌，于2020-07-17行心脏射频消融术+室间隔消融术。手术过程：消融前分别应用测压导管于心尖部、主动脉瓣下、瓣上，分别测压示：179/4/57、99/36/47 mmHg、110/56/63 mmHg。在CartoSound超声导管至右室行左室三维重建，重点重建室间隔，送消融导管至室间隔最厚部位及二尖瓣SAM时与室间隔的接触部位(心腔内超声下可见此处SAM征阳性)，标测正常传导束，避开P电位区域，以43℃、40 W放电消融。消融后再次将测压导管先后至心尖部、主动脉瓣上、瓣下，分别测压示124/5/64、94/49/57 mmHg、115/55/64 mmHg。在CARTO指导下行左房三维重建，行环肺静脉前庭消融，同时附加二尖瓣峡部线、三尖瓣峡部线、左房顶部线、左房前壁线及左房底部线消融。LOVT压差由术前约80降至30 mmHg，流出道梗阻解除。(见图3)。术后给予可达龙控制心室率、拜瑞妥抗凝、雷贝拉唑抑酸治疗。术后7天复查心电图：① 窦性心律；② 左室高电压；③ Ptfv1 ≤ 0.04 mm&#183;s；④ II.III.aVF导联可见P波双峰；⑤ ST-T改变(见图1，C)。心脏超声：左室舒张末期内径42 mm，射血分数66%，左房扩大，左心室壁非均匀性增厚，室间隔最厚处14 mm，左室后壁厚14 mm，室间隔与左室后壁之比约1，收缩期左室流出道前向血流流速增快，峰值流速2.0 m/s，峰值压差约29 mmHg。① 考虑肥厚型心肌病 左房扩大(轻度) ② 主动脉瓣反流(轻度)二尖瓣反流(轻度)三尖瓣反流(轻度) ③ 左室舒张功能减低 ④ 肺动脉高压(轻度) ⑤ 心包积液(微量) (见图2，G)。</p><p>图1. A为2017年检查时心电图。B为此次入院时心电图。C为术后7天心电图</p><p>图2. E为2017年检查时心脏超声。F为此次入院时心脏超声。G为术后7天心脏超声</p><p>图3. H为房颤消融靶点图。I为室间隔消融靶点图</p></sec><sec id="s6"><title>2. 讨论</title><p>肥厚型梗阻性心肌病(HOCM)是一种以心室非对称性肥厚为特征，以致命性心律失常、心力衰竭及心源性猝死等为临床的表现的常染色体显性遗传病。目前，HOCM的发病率为1:500~1:200 [<xref ref-type="bibr" rid="hanspub.38479-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.38479-ref2">2</xref>]，病死率可达1.4%~2.2% [<xref ref-type="bibr" rid="hanspub.38479-ref3">3</xref>]。HOCM患者初期一般无明显临床表现，仅表现为心脏结构和血流动力学的改变，一旦患者出现胸痛、胸闷、呼吸困难、心悸、晕厥等症状，提示心脏结构改变较重，心脏射血受阻，血流动力学异常，预后越差 [<xref ref-type="bibr" rid="hanspub.38479-ref4">4</xref>]。目前，对于HOCM的治疗主要包括：① 有症状患者：药物治疗(β受体阻滞剂，(I，B))、室间隔消减治疗(经皮室间隔心肌消融术 [<xref ref-type="bibr" rid="hanspub.38479-ref5">5</xref>] 和外科室间隔切除术)、双腔起搏器。② 无症状患者：定期临床评估，不推荐室间隔消减治疗 [<xref ref-type="bibr" rid="hanspub.38479-ref4">4</xref>]。</p><p>研究表明，HOCM合并房颤患病率是普通人群的4~6倍 [<xref ref-type="bibr" rid="hanspub.38479-ref6">6</xref>]，伍等在一项回顾性研究分析中发现，HOCM患者中合并房颤的比例为17.5%，远高于普通人群 [<xref ref-type="bibr" rid="hanspub.38479-ref7">7</xref>]。心房纤维化在AF的发展和维持中起着重要作用，而HOCM患者由于心脏结果的改变，导致患者心脏收缩期发生二尖瓣前移导致二尖瓣反流和流出道受阻，引起左室舒张功能障碍及左室压力升高，导致慢性心房扩张和心房，最终进展为弥漫性心房纤维化 [<xref ref-type="bibr" rid="hanspub.38479-ref8">8</xref>]，这可能为HOCM合并AF患病率升高的主要原因。由于HOCM患者心脏结构存在不可逆性结构改变，导致AF合并HOCM患者单用抗心律失常药物治疗效果欠佳，持续快速的心房率导致房室的不同步收缩、舒张，使得左房舒张功能进一步降低，左房压力持续升高，加剧了左房心肌重构，形成恶性循环，最终发展为永久性房颤。长此以往，快速的心房率和HOCM导致的心脏结构改变导致机体血流动力学发生异常，进而出现心功能不全的临床表现，出现呼吸困难、肺水肿、心肌缺血、猝死等症状，活动耐力明显下降，生活质量极差，甚至出现急性左心衰竭/心源性猝死等。因此，早诊断、早干预、及时行介入治疗对于患者预后具有重要意义。目前，对于治疗药物控制不佳的HOCM合并AF患者的方法主要有两种，即外科手术切除左室流出道梗阻心肌部位联合导管消融术和室间隔酒精消融术联合导管消融术。证据表明，采用Morrow手术联合导管消融术，可以显著降低左室流出道压差(LVOTG)和缓解SAM征，而导管消融术可使2/3的AF患者在1~2年内不在复发 [<xref ref-type="bibr" rid="hanspub.38479-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.38479-ref9">9</xref>]。经导管注射无水酒精于室间隔心肌血管处，可使局部心肌发生变性坏死，也可有效降低流出道梗阻。虽然这两种术式均能有效解除流出道梗阻，降低LVOTG，明确改善患者临床症状。但由于外科手术需要胸骨切开术和体外循环，风险极高，酒精化学消融需注射乙醇量过多会导致穿孔和解剖异常(交通支血管)引起其他部位心肌梗死、束支传导阻滞等并发症。安全、有效、消融范围可控的心腔内超声指导下的室间隔射频消融术(RFCA)被越来越多的专家所认可。既往欧美国家的心脏中心将射频消融术应用于HOCM的治疗，其安全性和疗效已经得到了初步验证 [<xref ref-type="bibr" rid="hanspub.38479-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.38479-ref11">11</xref>]。在心腔内超声指导下的室间隔射频消融术(RFCA)，可于室间隔肥厚部位进行靶点消融，且不受间隔支动脉解剖变异影响。在三维电生理标测系统支持下，通过对正常传导束：房室结、希氏束、左右束支进行精准标测，有效避免正常传导束损伤，有效降低房室传导阻滞等并发症的发生。同时联合环肺静脉隔离结合基质改良治疗AF。两种手术方案联合治疗，既能解除梗阻降低LOVT压差、改善症状，又能同步治疗AF，为HOCM合并AF患者提供一种安全有效的替代治疗方案。研究表明HOCM进行室间隔射频消融可有效改善梗阻，降低LVOTG，术后患者预后得到有效改善 [<xref ref-type="bibr" rid="hanspub.38479-ref10">10</xref>]。根据《中国成人肥厚型心肌病诊断与治疗指南》，该患者心脏超声示室间隔肥厚且SAM征阳性且具有特异性心脏杂音：胸骨左缘3、4肋间可闻及粗糙的3/6级收缩期喷射样杂音，患者明确诊断为肥厚性梗阻型心肌病，患者同时合并房颤需行心脏射频消融术，虽然患者LOVT压差并无明显增大，但患者为中年男性，有猝死高危风险，且患者对于外科手术尚有顾虑，给予行室间隔射频消融术联合肺静脉隔离结合基质改良治疗。本案例将房颤射频消融和肥厚梗阻性心肌病室间隔射频消融术同时进行，室间隔射频消融为微创治疗，可精确去除梗阻区域，不用考虑间隔支动脉解剖结构及变异，术前标记His及束支的位置，较手术切除梗阻部位心肌和酒精间隔消融术更能有效避免伤及His及束支，并避免术后起搏器的植入且避免手术造成的创伤应激。患者目前仍处于随访过程中，目前患者症状明显改善，手术效果显著。</p></sec><sec id="s7"><title>声明</title><p>该病例报道已获得病人的知情同意。</p></sec><sec id="s8"><title>文章引用</title><p>陈 超,魏玉娇,张 浩,许丰强,李 姗,路 军,安 毅. 房颤合并肥厚型梗阻性心肌病心腔内超声指导下行肺静脉隔离附加室间隔消融一例Catheter Ablation with CARTO Sound Technology of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Case Report[J]. 临床医学进展, 2020, 10(11): 2433-2438. https://doi.org/10.12677/ACM.2020.1011367</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38479-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Maron, B.J., et al. (2003) American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 42, 1687-1713.  
&lt;br&gt;https://doi.org/10.1016/S0735-1097(03)00941-0</mixed-citation></ref><ref id="hanspub.38479-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Semsarian, C., et al. (2015) New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 65, 1249-1254. &lt;br&gt;https://doi.org/10.1016/j.jacc.2015.01.019</mixed-citation></ref><ref id="hanspub.38479-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">O’Mahony, C. and Elliott, P.M. (2014) Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Heart, 100, 254-260. &lt;br&gt;https://doi.org/10.1136/heartjnl-2012-301996</mixed-citation></ref><ref id="hanspub.38479-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会, 中国成人肥厚型心肌病诊断与治疗指南编写组, 中华心血管病杂志编辑委员会. 中国成人肥厚型心肌病诊断与治疗指南[J]. 中华心血管病杂志, 2017, 45(12): 1015-1032.</mixed-citation></ref><ref id="hanspub.38479-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., et al. (2018) Echocardiography Guided Liwen Procedure™ for the Treatment of Obstructive Hypertrophic Cardiomyopathy in a Patient with Prior Aortic Valve Replacement Surgery. Echocardiography, 35, 1230-1232.  
&lt;br&gt;https://doi.org/10.1111/echo.14040</mixed-citation></ref><ref id="hanspub.38479-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Guttmann, O.P., et al. (2014) Atrial Fibrillation and Thromboembolism in Patients with Hypertrophic Cardiomyopathy: Systematic Review. Heart, 100, 465-472. &lt;br&gt;https://doi.org/10.1136/heartjnl-2013-304276</mixed-citation></ref><ref id="hanspub.38479-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">伍熙, 崔颢, 王婧金, 肖明虎, 鲁洁, 郑欣馨, 郭颖, 王水云, 黄晓红. 梗阻性肥厚型心肌病合并心房颤动的临床特征及危险因素[J]. 中华内科杂志, 2017, 56(3): 184-187.</mixed-citation></ref><ref id="hanspub.38479-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Pujadas, S., et al. (2010) Correlation between Myocardial Fibrosis and the Occurrence of Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Imaging study. European Journal of Radiology, 75, e88-e91.  
&lt;br&gt;https://doi.org/10.1016/j.ejrad.2009.12.012</mixed-citation></ref><ref id="hanspub.38479-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, D.-S., et al. (2016) Outcomes of Catheter Ablation of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. Europace, 18, 508-520.  
&lt;br&gt;https://doi.org/10.1093/europace/euv339</mixed-citation></ref><ref id="hanspub.38479-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lawrenz, T., et al. (2011) Endocardial Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy: Acute Results and 6 Months’ Follow-Up in 19 Patients. Journal of the American College of Cardiology, 57, 572-576.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2010.07.055</mixed-citation></ref><ref id="hanspub.38479-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sreeram, N., Emmel, M. and de Giovanni, J.V. (2011) Percutaneous Radiofrequency Septal Reduction for Hypertrophic Obstructive Cardiomyopathy in Children. Journal of the American College of Cardiology, 58, 2501-2510.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2011.09.020</mixed-citation></ref></ref-list></back></article>